Starting Dose of Vraylar (Cariprazine)
The starting dose of Vraylar depends on the indication: 1.5 mg once daily for adults with schizophrenia, bipolar depression, or major depressive disorder (as adjunctive therapy); 1.5 mg once daily for adults with bipolar mania (increased to 3 mg on Day 2); and 0.5 mg once daily for pediatric patients (ages 10-17) with bipolar mania or (ages 13-17) with schizophrenia 1.
Adult Dosing by Indication
Schizophrenia
- Start: 1.5 mg once daily
- May increase to 3 mg on Day 2 if tolerated
- Therapeutic range: 1.5-6 mg daily
- Maximum: 6 mg daily
- Dose adjustments in 1.5 or 3 mg increments based on response 1
Bipolar Mania (Acute Manic or Mixed Episodes)
- Start: 1.5 mg once daily
- Increase to 3 mg on Day 2 (this is the key difference from other indications)
- Therapeutic range: 3-6 mg daily
- Maximum: 6 mg daily 1
Bipolar Depression
- Start: 1.5 mg once daily
- May increase to 3 mg on Day 15 if needed
- Maximum: 3 mg daily
- Note: Slower titration than mania 1
Major Depressive Disorder (Adjunctive to Antidepressants)
- Start: 1.5 mg once daily
- May increase to 3 mg on Day 15 if needed
- Maximum: 3 mg daily
- Critical: Titration intervals less than 14 days resulted in higher adverse event rates in trials 1
Pediatric Dosing
Ages 13-17 (Schizophrenia) or 10-17 (Bipolar Mania)
- Start: 0.5 mg once daily
- Increase to 1.5 mg on Day 3
- May increase to 3 mg on Day 5
- May increase to 4.5 mg on Day 8
- Maximum: 4.5 mg daily 1
Critical Dosing Considerations
Pharmacokinetic Properties
Cariprazine has an exceptionally long half-life due to its active metabolites (didesmethylcariprazine). Changes in dose will not be fully reflected in plasma for several weeks, requiring prolonged monitoring after any dose adjustment 1. The plasma concentration declines by only 50% in approximately 1 week after discontinuation 1.
Drug Interactions: CYP3A4 Inhibitors
When starting Vraylar while on a CYP3A4 inhibitor:
Strong CYP3A4 inhibitors (e.g., ketoconazole):
- Adults: Start 0.5 mg daily (may increase to 0.75 mg if needed for schizophrenia)
- Pediatrics: Not recommended 1
Moderate CYP3A4 inhibitors (e.g., erythromycin):
- Adults: Start 0.75 mg daily (may increase to 1.5 mg if needed for schizophrenia)
- Pediatrics: Not recommended 1
If adding a CYP3A4 inhibitor to stable Vraylar:
- Reduce current dose of 1.5-3 mg to 0.5 mg (strong inhibitor) or 0.75 mg (moderate inhibitor)
- Reduce current dose of 4.5-6 mg to 0.75 mg (strong inhibitor) or 1.5 mg (moderate inhibitor) 1
Recent PBPK modeling demonstrated that prolonged coadministration with strong CYP3A4 inhibitors can increase total cariprazine exposure up to 6-fold at steady state, necessitating these dose reductions 2.
CYP3A4 Inducers
Concomitant use with CYP3A4 inducers is not recommended as it has not been evaluated and may significantly reduce efficacy 1.
Administration Details
- Can be taken with or without food 1
- Once daily dosing
- Available only in capsule form (limits dose adjustments to 1.5 mg increments) 3
Common Pitfalls to Avoid
Titrating too quickly in MDD: The FDA label specifically warns that intervals less than 14 days increased adverse events 1
Expecting immediate dose effects: Due to the long half-life, monitor patients for adverse reactions and treatment response for several weeks after starting or changing doses 1
Switching from D2 antagonists: When switching from full D2 antagonists to cariprazine (a partial D2 agonist), cross-titration is recommended to avoid potential symptom worsening 3
Ignoring drug interactions: Failure to adjust for CYP3A4 inhibitors can lead to significantly elevated plasma levels and increased adverse effects 2
Inadequate contraception: Effective contraception is required for females of childbearing age 4